These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 7851086

  • 1. Increased in vitro activity of ceftriaxone by addition of tazobactam against clinical isolates of anaerobes.
    Aldridge KE, Morice N, Schiro DD.
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):227-34. PubMed ID: 7851086
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
    Wüst J, Hardegger U.
    Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):177-81. PubMed ID: 8013494
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
    Appelbaum PC, Spangler SK, Jacobs MR.
    J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro activity of YTR 830.
    Jacobs MR, Aronoff SC, Appelbaum PC, Yamabe S.
    J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The sensitivity of clinical isolates of anaerobic species to piperacillin-tazobactam and other antimicrobial agents.
    Namavar F, Severin WP, Stobberingh E, Smeets T, MacLaren DM.
    J Antimicrob Chemother; 1994 Sep; 34(3):415-9. PubMed ID: 7829416
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
    Klepser ME, Marangos MN, Zhu Z, Nicolau DP, Quintiliani R, Nightingale CH.
    Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S, Hanaki H, Nagayama A.
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.
    Aldridge KE, Morice N, Schiro DD.
    Antimicrob Agents Chemother; 1994 Apr; 38(4):889-93. PubMed ID: 8031067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.